Follow Incyte to never miss an important update.
Brazilian health authorities granted expedited approval for Niktimvo to treat chronic graft-versus-host disease, a condition where donated immune cells attack the recipient's body after a transplant. The approval covers adults and children who have not seen success with at least two other therapies.
While this specific approval was secured by a partner firm, Knight Therapeutics, it expands the global reach for one of the newer drugs in the company's pipeline. This helps the business grow its revenue from specialized treatments as it works to reduce its reliance on its single largest product, Jakafi.
Source: GlobeNewsWire
Incyte shared new data from its portfolio of skin and autoimmune treatments at the European Academy of Dermatology and Venereology Congress. The presentations highlighted the company's efforts to expand beyond its current products into new areas of immunology.
This is a key part of the company's plan to diversify its revenue. While Incyte is currently known for its blood cancer treatments, it is working to build a second major business in dermatology. Showing progress with these new treatments helps prove it can successfully move into these new markets.
Source: Business Wire
Incyte is expanding its reach for Opzelura, a cream used to treat inflammatory skin conditions, through a new deal in Australia. The company will work with Specialised Therapeutics to handle the distribution and sale of the treatment there.
This move is part of a broader push to grow Opzelura into a multi-billion dollar product. While the drug is already a key part of Incyte's growth, expanding into new countries helps the company diversify its income before its main blood cancer drug loses patent protection later this decade.
Source: PRNewsWire
Knight Therapeutics, which handles Incyte's cancer drug Minjuvi in Latin America, has applied for Brazilian approval to use the drug as a first-line treatment for certain adult patients. Currently, the drug is typically used for patients whose cancer has returned or failed to respond to earlier treatments. While Brazil is a smaller market for Incyte compared to the U.S., moving a drug from a backup option to a first-line treatment is a standard way to reach more patients. This filing is part of the broader effort to maximize the value of Incyte's existing portfolio while it waits for newer drugs in its pipeline to reach the market.
Source: GlobeNewsWire
Piper Sandler raised its target price for the stock from $110 to $130 on Monday. The firm kept its overweight rating, which is a way of saying they expect the stock to perform better than the broader market. This move brings the firm's target in line with the $130 average across all analysts who cover the company.
Source: Piper Sandler
Management has a history of delivering massive surprises that far exceed analyst expectations, suggesting the business is scaling faster than even the most optimistic forecasts can track.
| Expectation | |
|---|---|
| EPS | $-3.21 |
| Revenue | $1.47B |